Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the top high-conviction stocks to buy according to hedge funds.
Deutsche Bank cut the price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $366 from $440 on June 2 while maintaining a Sell rating on the shares
The stock also received a rating update from BofA on May 12, with the firm cutting the price target on the stock to $515 from $520 and reiterating a Buy rating on the shares. For additional reference, in its financial results for fiscal Q1, Intuitive Surgical, Inc. (NASDAQ:ISRG) reported that worldwide procedures for da Vinci and Ion combined grew around 17% compared to fiscal Q1 2025, with Da Vinci procedures growing approximately 16%, and Ion procedures growing approximately 39%. Revenue for the quarter came up to $2.77 billion, up 23% compared to $2.25 billion in the prior year period.
The company also reported that it placed 431 da Vinci surgical systems, compared with 367 in fiscal Q1 2025. Intuitive Surgical, Inc. (NASDAQ:ISRG) has an elaborate ecosystem of services and products that provide robotic-assisted surgical solutions and invasive care. Its products include the Ion Endoluminal and the Da Vinci Surgical systems.